Natalizumab in Multiple Sclerosis: Long-Term Management

Area of Science:

• Neurology
• Immunology
• Infectious Diseases

Background:

• Natalizumab is a highly effective monoclonal antibody for relapsing remitting multiple sclerosis (RRMS).
• Concerns exist regarding progressive multifocal leukoencephalopathy (PML), a JC virus (JCV) brain infection, associated with natalizumab use, especially after 24 doses or with prior immunosuppression.
• Patients on long-term natalizumab, with prior immunosuppressive drug use, or JCV antibody-positive require reassessment of treatment continuation versus withdrawal.

Purpose of the Study:

• To review strategies for managing natalizumab treatment after 24 doses.
• To analyze approaches for mitigating progressive multifocal leukoencephalopathy (PML) risk while preventing clinical and radiological rebound activity.
• To evaluate outcomes of natalizumab continuation, discontinuation with therapeutic suspension, or switching to alternative MS treatments.

Main Methods:

• Review of clinical trials and case reports.
• Analysis of natalizumab continuation versus discontinuation strategies.
• Examination of outcomes following switches to other first or second-line multiple sclerosis (MS) treatments.

Main Results:

• Discontinuing all MS treatment after natalizumab increases the occurrence of MS activity.
• Outcomes following therapeutic switches after natalizumab are not uniform.
• No established guidelines exist for natalizumab treatment post-24 administrations; decisions rely on neurologist expertise and patient factors.

Conclusions:

• Managing natalizumab treatment beyond 24 doses presents a challenge in balancing PML risk with MS disease control.
• Current evidence does not support a definitive strategy for treatment continuation or switching.
• Individualized patient care, considering clinical features and neurologist experience, guides decisions in the absence of clear guidelines.